The peptide demonstrates remarkable stability compared to other compounds in its class
The latest GLP-1 drug approved for weight loss, tirzepatide, sold as Zepbound, appears to beat out semaglutide with nearly 19 percent of body weight lost, over 40 pounds (18 kg), with more like five and a half inches (14 cm) off the waist
Exploring the role of a novel peptide from Allomyrina dichotoma larvae in ameliorating lipid metabolism in obesity
Italy Spain Rest of Europe Asia Pacific China Japan India South Korea South-east Asia Rest of Asia Pacific Latin America Brazil Argentina Rest of Latin America Middle East & Africa GCC Countries South Africa Rest of the Middle East and Africa Regional Analysis: North America The North America GLP-1 Receptor Agonist Market size was valued at USD 11,474.32 million in 2018 to USD 21,092.81 million in 2024 and is anticipated to reach USD 81,088.80 million by 2032, at a CAGR of 18.4% during the forecast period
Levothyroxine is a sensitive medication that is best absorbed on an empty stomach